TY - JOUR
T1 - A Korean Kindred with Autosomal Dominant Nocturnal Frontal Lobe Epilepsy and Mental Retardation
AU - Cho, Yong Won
AU - Motamedi, Gholam K.
AU - Laufenberg, Iris
AU - Sohn, Sung Il
AU - Lim, Jeong Geun
AU - Lee, Hyung
AU - Yi, Sang Doe
AU - Lee, Ju Hwa
AU - Kim, Dae Kwang
AU - Reba, Richard
AU - Gaillard, William D.
AU - Theodore, William H.
AU - Lesser, Ronald P.
AU - Steinlein, Ortrud K.
PY - 2003/11
Y1 - 2003/11
N2 - Background: A Korean family had distinctive clinical and neuroimaging features and carried the same genetic mutation that was found in a previously described Japanese kindred with autosomal dominant nocturnal frontal lobe epilepsy. Objective: To describe the first Korean family with autosomal dominant nocturnal frontal lobe epilepsy. Methods: Members of a large family, including 9 affected individuals from 3 generations, underwent a comprehensive genetic, clinical, electroencephalographic, neuropsychological, and neuroimaging evaluation. Affected members were tested for possible mutations in transmembrane regions 1 through 3 of the neuronal nicotinic acetylcholine receptor α4 subunit (CHRNA4) by direct sequencing and subsequent restriction analysis. Results: Seizures began in childhood, presenting as nocturnal episodes of staring, confusion, shouting, perioral movements, unintelligible speech, and hand waving. Some patients had ictal or interictal epileptiform activity in the temporal and/or frontocentral areas. Neurological examination and brain magnetic resonance imaging results showed no abnormalities, except that all patients available for testing had mild to moderate mental retardation. Fluorodeoxyglucose F 18 with positron emission tomography showed mild decreased glucose uptake in the superior and middle frontal regions, more so on the left than on the right. Patient response to carbamazepine was poor. All affected members were heterozygous for the CHRNA4 Ser252Leu mutation. Conclusions: Disorders associated with mutations in the transmembrane region 2 of CHRNA4 are genetically and phenotypically heterogeneous. Distinctive features of this kindred include (1) mental retardation in all affected members available for testing, (2) abnormal brain findings on fluorodeoxyglucose F 18 with positron emission tomography, (3) poor response to carbamazepine, and (4) full penetrance.
AB - Background: A Korean family had distinctive clinical and neuroimaging features and carried the same genetic mutation that was found in a previously described Japanese kindred with autosomal dominant nocturnal frontal lobe epilepsy. Objective: To describe the first Korean family with autosomal dominant nocturnal frontal lobe epilepsy. Methods: Members of a large family, including 9 affected individuals from 3 generations, underwent a comprehensive genetic, clinical, electroencephalographic, neuropsychological, and neuroimaging evaluation. Affected members were tested for possible mutations in transmembrane regions 1 through 3 of the neuronal nicotinic acetylcholine receptor α4 subunit (CHRNA4) by direct sequencing and subsequent restriction analysis. Results: Seizures began in childhood, presenting as nocturnal episodes of staring, confusion, shouting, perioral movements, unintelligible speech, and hand waving. Some patients had ictal or interictal epileptiform activity in the temporal and/or frontocentral areas. Neurological examination and brain magnetic resonance imaging results showed no abnormalities, except that all patients available for testing had mild to moderate mental retardation. Fluorodeoxyglucose F 18 with positron emission tomography showed mild decreased glucose uptake in the superior and middle frontal regions, more so on the left than on the right. Patient response to carbamazepine was poor. All affected members were heterozygous for the CHRNA4 Ser252Leu mutation. Conclusions: Disorders associated with mutations in the transmembrane region 2 of CHRNA4 are genetically and phenotypically heterogeneous. Distinctive features of this kindred include (1) mental retardation in all affected members available for testing, (2) abnormal brain findings on fluorodeoxyglucose F 18 with positron emission tomography, (3) poor response to carbamazepine, and (4) full penetrance.
UR - http://www.scopus.com/inward/record.url?scp=10744228608&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10744228608&partnerID=8YFLogxK
U2 - 10.1001/archneur.60.11.1625
DO - 10.1001/archneur.60.11.1625
M3 - Article
C2 - 14623738
AN - SCOPUS:10744228608
SN - 0003-9942
VL - 60
SP - 1625
EP - 1632
JO - Archives of neurology
JF - Archives of neurology
IS - 11
ER -